Asset Management One Co. Ltd. Buys 3,057 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Asset Management One Co. Ltd. increased its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 6.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 52,844 shares of the company's stock after purchasing an additional 3,057 shares during the quarter. Asset Management One Co. Ltd. owned approximately 0.06% of IDEXX Laboratories worth $21,927,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Chicago Partners Investment Group LLC increased its position in IDEXX Laboratories by 16.7% during the 3rd quarter. Chicago Partners Investment Group LLC now owns 672 shares of the company's stock worth $340,000 after purchasing an additional 96 shares in the last quarter. National Pension Service grew its holdings in IDEXX Laboratories by 7.3% during the 3rd quarter. National Pension Service now owns 185,972 shares of the company's stock worth $93,957,000 after acquiring an additional 12,647 shares during the last quarter. Insight Wealth Strategies LLC grew its holdings in IDEXX Laboratories by 230.5% during the 4th quarter. Insight Wealth Strategies LLC now owns 10,096 shares of the company's stock worth $4,174,000 after acquiring an additional 7,041 shares during the last quarter. Larson Financial Group LLC grew its holdings in IDEXX Laboratories by 17,238.5% during the 3rd quarter. Larson Financial Group LLC now owns 2,254 shares of the company's stock worth $1,139,000 after acquiring an additional 2,241 shares during the last quarter. Finally, Quest Partners LLC grew its holdings in IDEXX Laboratories by 4,059.4% during the 3rd quarter. Quest Partners LLC now owns 2,870 shares of the company's stock worth $1,450,000 after acquiring an additional 2,801 shares during the last quarter. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the stock. StockNews.com lowered shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a report on Wednesday, February 5th. Leerink Partners initiated coverage on shares of IDEXX Laboratories in a research note on Monday, December 2nd. They issued an "outperform" rating and a $500.00 price objective on the stock. Bank of America upped their price objective on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the company a "neutral" rating in a research note on Tuesday, February 4th. Leerink Partnrs raised shares of IDEXX Laboratories to a "strong-buy" rating in a research note on Monday, December 2nd. Finally, Morgan Stanley reduced their price objective on shares of IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating on the stock in a research note on Wednesday, January 29th. Four investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $533.75.

Insider Buying and Selling

In other news, Director M Anne Szostak sold 3,000 shares of IDEXX Laboratories stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the completion of the transaction, the director now owns 3,061 shares in the company, valued at $1,426,242.34. This trade represents a 49.50 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP George Fennell sold 9,986 shares of IDEXX Laboratories stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the completion of the transaction, the executive vice president now owns 8,176 shares of the company's stock, valued at $3,781,645.28. The trade was a 54.98 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 13,330 shares of company stock worth $6,161,276. Insiders own 2.18% of the company's stock.

IDEXX Laboratories Stock Up 0.4 %

IDXX traded up $1.93 during trading on Wednesday, hitting $450.99. 499,898 shares of the company's stock were exchanged, compared to its average volume of 704,909. The business's 50 day moving average is $430.91 and its two-hundred day moving average is $452.43. The stock has a market cap of $36.93 billion, a P/E ratio of 42.27, a PEG ratio of 3.35 and a beta of 1.37. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. IDEXX Laboratories, Inc. has a fifty-two week low of $398.50 and a fifty-two week high of $583.39.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.